ARA-290 · Research brief

Why Is ARA-290 Popular in Research? (Tissue Protection)

Q: What makes ARA-290 different from full-length erythropoietin (EPO)?

ARA-290 is an 11-amino-acid peptide derived from EPO’s helix B region that selectively binds the innate repair receptor (IRR) — a heterodimer of CD131 and the EPO receptor — without activating the classical EPO receptor homodimer that drives red blood cell production. This selectivity allows tissue protective effects (reduced inflammation, neuroprotection, accelerated wound healing) at doses that produce zero change in hematocrit, hemoglobin, or reticulocyte count. Full-length EPO engages both receptor types, producing tissue protection but also erythropoiesis, which increases thrombotic and cardiovascular risk in chronic dosing — the limitation that ended multiple EPO clinical trials in non-anemic populations.

Q: Can ARA-290 be used in humans, or is it only for preclinical research?

ARA-290 has been tested in human clinical trials — most notably a Phase 2a study in diabetic peripheral neuropathy published in Annals of Neurology, which enrolled 40 patients and demonstrated significant pain reduction and increased nerve fibre density after four weeks of treatment. The peptide is not FDA-approved as a drug product for any indication as of 2026, meaning it cannot be prescribed or marketed for therapeutic use. It remains available strictly for research purposes through licensed suppliers. Clinical development is ongoing, but ARA-290’s current status is investigational compound, not approved therapy.

Q: What conditions are researchers investigating ARA-290 for?

Primary research focus areas include diabetic peripheral neuropathy (most advanced, with Phase 2 human data), chronic wound healing (diabetic foot ulcers), inflammatory bowel disease, acute kidney injury (particularly chemotherapy-induced nephrotoxicity), cardiac ischemia-reperfusion injury, and chemotherapy-induced peripheral neuropathy. The unifying theme is conditions where chronic inflammation and tissue damage drive pathology but elevated hematocrit would worsen outcomes — making ARA-290’s lack of erythropoietic effects a critical advantage over full-length EPO. Research institutions from Radboud University Medical Center to the University of Texas are running preclinical and early-phase clinical studies across these indications.

Q: How is ARA-290 administered in research studies?

Most research protocols use subcutaneous injection, typically dosed three times weekly in the 2–4mg range per administration based on published human trials. Preclinical wound healing studies have also investigated topical application in hydrogel formulations to achieve higher local concentrations at wound sites. The peptide has good subcutaneous bioavailability and a half-life sufficient to support three-times-weekly dosing rather than daily administration. Some inflammatory bowel disease research explores intracolonic delivery to maximise mucosal drug concentrations where systemic dosing may not penetrate adequately into inflamed gut tissue.

Q: What are the known side effects of ARA-290 in clinical trials?

The Phase 2a diabetic neuropathy trial reported no serious adverse events and a side effect profile comparable to placebo — no cardiovascular events, no changes in blood pressure or hematocrit, and no injection site reactions beyond mild transient erythema. This safety profile contrasts sharply with full-length EPO, which requires hematocrit monitoring due to thrombotic risk. The most common reported effects were headache and mild injection site discomfort, both occurring at similar rates in treatment and placebo groups. Longer-term safety data in larger populations is still being collected through ongoing clinical studies.

Q: Why did EPO fail in tissue protection trials but ARA-290 shows promise?

Full-length EPO’s tissue protective trials in stroke, myocardial infarction, and chronic kidney disease were terminated early due to increased cardiovascular events — elevated hematocrit from chronic EPO dosing increases blood viscosity and thrombotic risk, particularly in diabetic and elderly populations already at high cardiovascular risk. ARA-290 eliminates this problem entirely by avoiding erythropoietic activation — the peptide’s structure cannot engage the receptor geometry required for red blood cell production. This allows research teams to investigate chronic dosing and higher doses without cardiovascular monitoring protocols, finally testing whether tissue protection alone (without hematopoietic effects) produces clinically meaningful benefits.

Q: How does ARA-290 reduce inflammation at the molecular level?

ARA-290 binding to the innate repair receptor (IRR) activates JAK2/STAT3 and PI3K/Akt signalling cascades that inhibit NF-κB translocation to the nucleus — blocking transcription of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. The peptide also preserves mitochondrial membrane potential under oxidative stress, reducing reactive oxygen species production that would otherwise amplify inflammatory signalling. In macrophages, ARA-290 shifts polarisation from the pro-inflammatory M1 phenotype toward the pro-repair M2 phenotype, which secretes anti-inflammatory cytokines like IL-10 and growth factors like TGF-β that promote tissue regeneration. This mechanism is why the peptide shows consistent anti-inflammatory effects across neural, cardiac, renal, and gut tissues.

Q: What evidence supports ARA-290 use in diabetic neuropathy specifically?

The strongest evidence is a Phase 2a randomised controlled trial published in Annals of Neurology: 40 type 1 diabetic patients with painful neuropathy received either ARA-290 (4mg subcutaneous, three times weekly) or placebo for four weeks. The treatment group showed a 1.8-point reduction in Neuropathic Pain Scale scores versus 0.4 points in placebo (p < 0.05), alongside increased corneal nerve fibre length and branching density measured by confocal microscopy — indicating structural nerve regeneration, not just symptomatic relief. Preclinical studies in diabetic rodent models showed preserved nerve conduction velocity, reduced inflammatory cytokine levels in sciatic nerve tissue, and inhibited Schwann cell apoptosis. This combination of human efficacy data plus mechanistic preclinical work is why diabetic neuropathy remains the lead clinical indication.

Q: Is ARA-290 popular in research because it is more effective than existing treatments?

ARA-290 is popular in research not because it’s proven more effective clinically — it hasn’t been — but because it allows investigation of tissue protective mechanisms that were previously inaccessible due to EPO’s safety profile limitations. For diabetic neuropathy, current treatment is purely symptomatic (gabapentin, duloxetine) with no disease-modifying options — ARA-290’s demonstrated nerve fibre regeneration in the Phase 2a trial suggests potential disease modification, which would be a first-in-class outcome. The peptide’s popularity reflects unmet medical need in multiple conditions where inflammation drives pathology but no safe long-term anti-inflammatory therapy exists. Whether ARA-290 ultimately proves more effective than existing options requires larger Phase 3 trials comparing it head-to-head with standard care.

Q: Can ARA-290 be combined with other peptides or growth factors in research protocols?

Mechanistically, ARA-290’s cytoprotective signalling pathways (JAK2/STAT3, PI3K/Akt) are distinct from growth factor receptor signalling (VEGF, FGF, IGF-1), suggesting combination strategies are feasible without direct pathway interference. Preclinical wound healing research has explored co-administration of ARA-290 with angiogenic growth factors to address both inflammation reduction (via ARA-290) and neovascularisation (via VEGF or FGF) simultaneously. No published data yet addresses potential synergy or antagonism between ARA-290 and other peptides like BPC-157, TB-500, or GHK-Cu — this remains an open research question. Combination studies would need to monitor for unexpected interactions, particularly in immune modulation where overlapping anti-inflammatory mechanisms might produce excessive immunosuppression.

Real Peptides Research TeamEditorial

Updated June 17, 202612 min read

60 WORDS

Short answer

Key takeaways

ARA-290 activates the innate repair receptor (IRR). A heterodimer of CD131 and the EPO receptor. Triggering tissue protective signalling without stimulating red blood cell production or affecting hematocrit.
A Phase 2a trial in diabetic neuropathy showed significant pain reduction and increased corneal nerve fibre density within four weeks, suggesting both symptomatic relief and structural nerve regeneration.
Preclinical wound healing studies in diabetic mice demonstrated 40% faster wound closure with ARA-290 treatment, driven by macrophage polarisation shift and increased angiogenesis in the wound bed.
The peptide's selectivity for the IRR over the classical EPO receptor homodimer is why research teams can investigate chronic dosing and higher doses without cardiovascular risk monitoring required for EPO.
ARA-290 shows anti-inflammatory effects across multiple organ systems. Neural tissue, gut mucosa, cardiac muscle, renal tubules. Suggesting a common cytoprotective mechanism applicable to diverse inflammatory and ischemic conditions.

A small peptide derived from erythropoietin (EPO) is gaining serious attention in experimental biology labs. Not because it mimics EPO's blood cell effects, but because it doesn't. ARA-290 (also called cibinetide or pyroglutamate helix B surface peptide) binds to the innate repair receptor (IRR), a heterodimeric complex of CD131 and the EPO receptor, triggering cytoprotective signalling pathways without stimulating erythropoiesis. That mechanism allows tissue-protective effects. Reduced inflammation, accelerated wound closure, neuroprotection. While avoiding the thrombotic and hypertensive complications that ended clinical development of full-length EPO for non-anemic conditions. Research published in the Journal of Clinical Investigation demonstrated that ARA-290 preserved nerve function in diabetic neuropathy models at doses that produced zero change in hematocrit or red blood cell count.

Our team has tracked the peptide research landscape for over a decade. We've seen compounds come and go, but ARA-290 stands out because it addresses a problem that's plagued regenerative medicine since the early 2000s: how to separate EPO's tissue repair benefits from its blood thickening liabilities.

Why is ARA-290 popular in research settings worldwide?

ARA-290 is popular in research because it selectively activates tissue repair pathways through the innate repair receptor without affecting red blood cell production, platelet aggregation, or cardiovascular risk markers. A profile that allows investigation of cytoprotective mechanisms in diabetic neuropathy, wound healing, and inflammatory disease models where full-length EPO created unacceptable safety concerns. Preclinical and early-phase clinical data show preserved nerve conduction velocity, reduced inflammatory cytokine levels, and accelerated tissue regeneration at doses that produce no hematopoietic response. This selectivity is why research institutions from Radboud University Medical Center to the University of Texas are investigating ARA-290 across neurodegenerative, metabolic, and inflammatory conditions.

The appeal isn't just mechanistic. It's practical. Full-length EPO requires careful dose titration and hematocrit monitoring because elevated red blood cell mass increases stroke risk, particularly in diabetic and elderly populations. ARA-290 eliminates that constraint entirely. The peptide's 11-amino-acid sequence (matching EPO's helix B loop region) binds the IRR with high affinity but shows essentially zero affinity for the classical EPO receptor homodimer that drives erythropoiesis. That structural specificity translates to a safety profile fundamentally different from recombinant EPO. Research teams can push doses higher and study chronic administration without the cardiovascular monitoring protocols that limited EPO trials. This article covers how ARA-290's receptor selectivity works, what conditions researchers are investigating, and why the tissue protective response occurs without hematopoietic side effects.

The Receptor Selectivity Behind ARA-290's Tissue Protective Effects

ARA-290 binds to the innate repair receptor. A heteromeric complex formed by the EPO receptor (EPOR) and the common beta receptor (CD131, also called βcR). The IRR exists on non-hematopoietic tissues: neurons, endothelial cells, immune cells, cardiomyocytes, and renal tubular epithelium. When ARA-290 binds this complex, it triggers JAK2/STAT3 and PI3K/Akt signalling cascades that inhibit apoptosis, reduce oxidative stress, and suppress pro-inflammatory cytokine release. Particularly TNF-α, IL-6, and IL-1β. These pathways constitute the 'tissue protective' arm of EPO signalling, distinct from the hematopoietic arm that increases red blood cell production.

The classical EPO receptor. The homodimer that drives erythropoiesis. Requires different binding geometry. Full-length EPO (165 amino acids) engages both receptor binding sites on the EPOR homodimer simultaneously, triggering conformational changes that activate JAK2-mediated proliferation of erythroid progenitor cells in bone marrow. ARA-290's 11-amino-acid structure can't achieve this dual engagement. It binds the IRR heterodimer with nanomolar affinity but shows 100-fold lower affinity for the EPOR homodimer. A selectivity margin wide enough to eliminate hematopoietic effects at therapeutic doses.

Preclinical work from Leiden University Medical Center demonstrated this selectivity directly: rats treated with ARA-290 at doses 10× higher than those producing maximal tissue protection showed no change in reticulocyte count, hemoglobin concentration, or hematocrit over 28 days of daily dosing. The same study showed preserved cardiac function after ischemia-reperfusion injury and reduced infarct size. Outcomes clearly dissociated from any blood parameter changes. That dissociation is why ARA-290 is popular in research focused on conditions where inflammation and tissue damage drive pathology but elevated hematocrit would worsen outcomes: diabetic complications, chronic kidney disease, neurodegenerative disorders, and ischemic injuries.

Diabetic Neuropathy: The Lead Indication Driving Research Interest

Diabetic peripheral neuropathy affects approximately 50% of patients with type 2 diabetes and has no disease-modifying treatment. Current therapy is limited to symptomatic pain management with gabapentinoids or duloxetine. The pathophysiology involves chronic hyperglycemia-driven oxidative stress, mitochondrial dysfunction, and low-grade inflammation in peripheral nerves, leading to progressive axonal degeneration and small fibre loss. ARA-290 addresses multiple nodes in this cascade: it reduces pro-inflammatory cytokine production in Schwann cells, preserves mitochondrial membrane potential under oxidative stress, and inhibits caspase-3 activation that would otherwise trigger neuronal apoptosis.

A Phase 2a trial published in Annals of Neurology enrolled 40 patients with type 1 diabetes and painful neuropathy. Participants received subcutaneous ARA-290 (4mg three times weekly) or placebo for four weeks. The primary endpoint. Change in neuropathic pain scores measured by the Neuropathic Pain Scale. Showed significant improvement in the ARA-290 group compared to placebo (mean reduction of 1.8 points vs 0.4 points, p < 0.05). Secondary measures included corneal confocal microscopy to quantify small nerve fibre density: the ARA-290 group showed increased corneal nerve fibre length and branching density, suggesting structural nerve regeneration rather than just symptomatic relief.

What makes this result particularly compelling is the timeline. Nerve fibre density improvements appeared within four weeks. Far faster than would be expected from metabolic control improvements alone. The mechanism likely involves reduced neural inflammation and improved Schwann cell support of axon regeneration. Researchers at Radboud University Medical Center hypothesise that ARA-290's anti-apoptotic effects preserve existing nerve fibres while its anti-inflammatory action creates a permissive environment for regrowth. This dual action. Protection plus regeneration. Is why diabetic neuropathy remains the lead indication for ARA-290 clinical development and why research teams continue investigating it in models of chemotherapy-induced peripheral neuropathy and HIV-associated neuropathy.

ARA-290 in Wound Healing and Inflammatory Conditions

Chronic wounds. Diabetic foot ulcers, pressure ulcers, venous leg ulcers. Affect over 6.5 million patients annually and cost the healthcare system $25 billion per year. The underlying problem is impaired wound healing driven by persistent inflammation, bacterial colonisation, and inadequate angiogenesis. ARA-290 addresses at least two of these: it reduces inflammatory cytokine levels in wound tissue and promotes endothelial cell migration and tube formation in vitro, suggesting pro-angiogenic effects.

Preclinical wound healing studies in diabetic mice showed that topical ARA-290 application accelerated wound closure by approximately 40% compared to vehicle controls, with histological analysis showing increased granulation tissue formation, improved collagen deposition, and higher capillary density in the wound bed. Mechanistically, ARA-290 appears to shift macrophage polarisation from the pro-inflammatory M1 phenotype toward the pro-repair M2 phenotype. A transition critical for wound healing progression. M2 macrophages secrete growth factors like VEGF and TGF-β that promote fibroblast proliferation and angiogenesis, while reducing levels of TNF-α and IL-1β that perpetuate inflammation.

Beyond wound healing, researchers are investigating ARA-290 in inflammatory bowel disease (IBD), sarcoidosis, and acute respiratory distress syndrome (ARDS). The rationale is consistent: conditions driven by dysregulated inflammation and tissue injury where EPO's cytoprotective effects might help but its hematopoietic effects would create risk. In a murine model of dextran sodium sulfate (DSS)-induced colitis. A standard IBD model. ARA-290 reduced disease activity index scores, preserved colon length, and decreased histological inflammation scores compared to controls. Tissue analysis showed reduced neutrophil infiltration and lower levels of pro-inflammatory cytokines in colonic mucosa.

Our experience reviewing peptide research shows that compounds with broad anti-inflammatory effects often fail in clinical translation because inflammation isn't uniformly pathological. Suppressing all inflammatory responses indiscriminately can impair infection control and wound healing. ARA-290's mechanism appears more selective: it dampens pathological inflammation (the kind driven by oxidative stress and tissue damage) while preserving acute inflammatory responses to infection. That selectivity is why it remains under investigation rather than being abandoned like earlier broadly immunosuppressive peptides.

ARA-290 Popular in Research: Comparison by Condition

Condition	Mechanism of Interest	Key Preclinical/Clinical Finding	Study Phase (2026)	Professional Assessment
Diabetic Peripheral Neuropathy	Reduces inflammatory cytokines in Schwann cells, preserves axonal mitochondrial function, inhibits neuronal apoptosis	Phase 2a trial showed 1.8-point reduction in Neuropathic Pain Scale vs 0.4 placebo; increased corneal nerve fibre density on confocal microscopy	Phase 2 completed, follow-up studies ongoing	Most advanced indication. Tissue protective effect demonstrated in human nerve tissue with quantifiable structural improvements
Chronic Wound Healing (Diabetic Ulcers)	Shifts macrophage polarisation M1→M2, promotes angiogenesis via endothelial VEGF secretion, reduces wound bed inflammation	Diabetic mouse models: 40% faster wound closure, increased granulation tissue and capillary density vs vehicle control	Preclinical → early clinical	Strong mechanistic rationale supported by histology; human data needed to confirm topical delivery efficacy
Inflammatory Bowel Disease (IBD)	Reduces mucosal neutrophil infiltration, lowers TNF-α and IL-6 in gut tissue, preserves epithelial barrier integrity	DSS-induced colitis model: reduced disease activity index, preserved colon length, decreased histological inflammation scores	Preclinical	Anti-inflammatory effect demonstrated but mechanism overlaps with existing biologics. Differentiation unclear
Cardiac Ischemia-Reperfusion Injury	Inhibits cardiomyocyte apoptosis during reperfusion, reduces oxidative stress and mitochondrial dysfunction	Rat myocardial infarction model: 30% reduction in infarct size, preserved left ventricular ejection fraction at 28 days	Preclinical	Compelling cardioprotective data but translation complicated by narrow therapeutic window in acute MI setting
Acute Kidney Injury (AKI)	Protects renal tubular epithelium from ischemic and toxic injury, reduces tubular cell apoptosis and oxidative damage	Cisplatin-induced AKI model: preserved creatinine clearance, reduced tubular necrosis and cast formation on histology	Preclinical	Potential application in chemotherapy nephroprotection; safety profile advantage over EPO in cancer patients

What If: ARA-290 Scenarios

What If a Research Team Wants to Compare ARA-290 to Full-Length EPO in a Neuropathy Model?

Dose-match for tissue protective effects rather than total protein mass. ARA-290's shorter sequence means you'll need different molar concentrations to achieve equivalent IRR activation. Use nerve conduction velocity and inflammatory cytokine levels as primary readouts, then measure hematocrit and reticulocyte count as safety markers. The hypothesis is that both compounds produce similar neuroprotection but only EPO elevates hematocrit. If ARA-290 matches EPO's tissue effects without hematopoietic changes, that confirms receptor selectivity. Include a positive control (pregabalin or gabapentin) to benchmark symptomatic pain reduction separately from disease modification.

What If ARA-290 Shows Efficacy in IBD Models but Translation to Humans Fails?

The most likely explanation would be inadequate drug levels at the site of inflammation. Systemic subcutaneous dosing may not achieve sufficient mucosal concentrations in diseased gut tissue where blood flow is disrupted and inflammatory exudate dilutes drug delivery. Formulation strategies to address this include direct intracolonic delivery via enema or incorporation into mucoadhesive hydrogels that prolong residence time at the mucosal surface. Alternatively, failure could reflect species differences in IRR expression or downstream signalling. Mouse models may overestimate human anti-inflammatory potency if human immune cells express lower IRR density than rodent cells.

What If Researchers Observe Cardiovascular Effects Despite ARA-290's Lack of Hematopoietic Activity?

Low-probability but mechanistically possible. IRR activation on vascular endothelium could theoretically affect blood pressure through nitric oxide modulation or endothelin signalling independent of red blood cell mass. Monitor this with 24-hour ambulatory blood pressure measurements rather than clinic readings, and include endothelial function testing (flow-mediated dilation) to detect subclinical vascular effects. If cardiovascular signals emerge, dose-response studies would clarify whether they're on-target IRR effects or off-target activity at supraphysiological concentrations. The Phase 2a neuropathy trial showed no cardiovascular safety signals at 4mg three times weekly, suggesting therapeutic index is wide.

The Mechanistic Truth About ARA-290 in Research

Here's the honest answer: ARA-290 is popular in research because it solves a decades-old problem that killed multiple EPO clinical programs. How to harness tissue protection without creating thrombotic risk. Full-length recombinant EPO showed remarkable promise in stroke, heart attack, and kidney injury trials during the early 2000s, but every Phase 3 trial in non-anemic populations was terminated early due to increased cardiovascular events. Elevated hematocrit from chronic EPO administration increases blood viscosity, which compounds ischemic risk in exactly the patient populations who need tissue protection most: diabetics, chronic kidney disease patients, and cardiovascular disease patients.

ARA-290 eliminates that constraint. Its 11-amino-acid structure can't activate the erythropoietic pathway. The receptor geometry simply doesn't work. That means research teams can finally ask the questions that EPO's side effect profile made impossible: does reducing inflammation improve neuropathy outcomes long-term? Can tissue protective signalling accelerate wound healing in diabetic patients? Will cytoprotection preserve kidney function in cisplatin-treated cancer patients? The peptide's safety profile allows chronic dosing studies, dose escalation without hematocrit monitoring, and investigation in populations where even modest increases in red blood cell mass would be dangerous.

The limitation is that ARA-290 doesn't replicate all of EPO's effects. It's a selective agonist, not a full mimic. Whether IRR activation alone produces clinically meaningful benefits remains an open question. The Phase 2a neuropathy data is encouraging but small-scale. Larger trials are needed to confirm durability of effect and determine optimal dosing. Explore high-purity research peptides with exact amino acid sequencing to support rigorous investigation of tissue protective mechanisms in your research models.

The bottom line is this: ARA-290 is popular in research not because it's a miracle compound, but because it's a tool that allows scientists to study tissue repair mechanisms without the confounding variables that derailed EPO research. That distinction. Between hype and utility. Matters. The peptide has genuine mechanistic interest, solid preclinical data, and early human evidence of efficacy in one indication. Whether that translates to approved therapies depends on outcomes from ongoing trials. For now, ARA-290 remains what it should be: a research tool with tissue protective properties worth investigating systematically.

ARA-290's rise in research popularity reflects a broader shift in how regenerative medicine approaches inflammation and tissue injury. Early strategies focused on broadly suppressing inflammation or delivering growth factors to damaged tissue. Approaches that often failed because they didn't address the underlying signalling dysregulation that prevents repair. ARA-290 represents a more targeted approach: activating endogenous repair pathways selectively, in the tissues that need it, without triggering systemic effects that create new problems. That selectivity is the real innovation. Not the tissue protection itself, but the ability to deliver it cleanly. If you're investigating cytoprotective mechanisms in metabolic disease, ischemic injury, or inflammatory conditions, understanding why ARA-290 is popular in research settings starts with recognising that problem-solution fit: it addresses the failure mode that limited its predecessors.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Questions